Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Strategic Expansion into AI-Powered Healthcare Solutions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News VIVESTO ADR OASMY

Healthcare Biotechnology Drug Manufacturers - Specialty & Generic
Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics,... see more

Recent & Breaking News (GREY:OASMY)

Glancy Prongay & Murray LLP Continues Investigation on Behalf of Oasmia Pharmaceutical AB Investors (OASM)

Business Wire July 17, 2019

SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Press Releases July 17, 2019

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Oasmia Pharmaceutical AB Investors (OASM)

Business Wire July 17, 2019

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire July 16, 2019

ROSEN, A TOP RANKED LAW FIRM, Continues to Investigate Securities Claims Against Oasmia Pharmaceutical AB - OASM

Business Wire July 16, 2019

Bragar Eagel & Squire, P.C. is Investigating Oasmia Pharmaceutical AB (NASDAQ: OASM) on Behalf of Stockholders and Encourages Investors to Contact the Firm

GlobeNewswire July 11, 2019

Glancy Prongay & Murray LLP Announces Investigation on Behalf of Oasmia Pharmaceutical AB Investors (OASM)

Business Wire July 11, 2019

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Oasmia Pharmaceutical AB Investors (OASM)

Business Wire July 11, 2019

OASMIA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Oasmia Pharmaceutical AB To Contact The Firm

GlobeNewswire July 11, 2019

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Oasmia Pharmaceutical AB (OASM)

Press Releases July 11, 2019

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Oasmia Pharmaceutical AB - OASM

Business Wire July 10, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Oasmia Pharmaceutical AB - OASM

GlobeNewswire July 10, 2019

OASMIA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Oasmia Pharmaceutical AB To Contact The Firm

PR Newswire June 28, 2019

European Medicines Agency validates Oasmia Pharmaceutical AB’s application to add efficacy data to the approved Apealea® product information

GlobeNewswire January 15, 2019

Thinking about buying stock in Ford, Fastenal, Oasmia Pharmaceutical, One Horizon Group or Zynga?

PR Newswire October 10, 2018

Oasmia Pharmaceutical Receives Positive CHMP Opinion for Apealea® (paclitaxel micellar) in the European Union

GlobeNewswire September 21, 2018

Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.

GlobeNewswire May 20, 2018

Oasmia Pharmaceutical receives market approval for its Anti-Cancer Drug Doxophos® in Russia

GlobeNewswire August 8, 2017

Oasmia Pharmaceutical enters into new exclusive marketing and distribution agreement concerning Russia and other CIS markets

GlobeNewswire June 14, 2017

18 Biggest Mid-Day Losers For Wednesday

Benzinga.com  March 1, 2017